S

    Silence Therapeutics PLC (SLN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.42
    -0.03 (-0.22%)

    Market Cap: $834.11M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(14/22)
    Avg Surprise
    +139.82%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.16
    Range$-0.34 - $-0.11
    4 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.20-19.9%
    60d ago$-0.19-15.9%
    30d ago$-0.17-5.2%
    7d ago$-0.17-5.2%
    Current$-0.16
    Revenue Consensus
    $20670
    Range$0 - $124000
    6 analysts
    Dec 31, 2026
    EPS Consensus$-0.34
    Range$-0.70 - $0.01
    2 analysts
    Revenue Consensus
    $-2837980
    Range$-2866720 - $-2700720
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.34---
    Sep 26EST
    		-$-0.16---
    Jun 26
    		$-0.26$-0.32+18.75%Beat+51.9%
    Mar 26
    		$-0.33$-0.23-44.36%Miss+45.0%
    Dec 25
    		$-0.27$-0.49+44.90%Beat-258.8%
    Sep 25
    		$-0.15$-0.21+28.57%Beat+79.5%
    Jun 25
    		$-0.54$-0.27-100.00%Miss-25.6%
    Mar 25
    		$-0.60$-0.41-46.34%Miss-1009.1%
    Dec 24
    		$0.17$-0.25+169.33%Beat+135.4%
    Sep 24
    		$-0.73$-0.13-461.54%Miss-170.4%
    Jun 24
    		$-0.43$-0.11-290.91%Miss-16.2%
    Mar 24
    		$-0.05N/A+52.71%Beat+54.3%
    Dec 23
    		$-0.48$-0.21-128.57%Miss-206.1%
    Sep 23
    		$-0.27$-0.38+28.95%Beat-221.0%
    Jun 23
    		$-0.37$-0.67+44.78%Beat-143.7%
    Mar 23
    		$-0.12$-0.15+21.28%Beat-12.3%
    Dec 22
    		$0.45$-0.01+3748.39%Beat+417.9%
    Sep 22
    		$-0.08N/A+58.18%Beat+43.6%
    Jun 22
    		$-0.15$-0.20+22.59%Beat+51.8%
    Mar 22
    		$-0.11$-0.19+44.76%Beat+81.0%
    Dec 21
    		$-0.14$-0.14-0.42%Miss+9.2%
    Sep 21
    		$-0.15$-0.15+1.97%Beat+16.0%
    Jun 21
    		$-0.31N/A-136.91%Miss-121.8%
    Mar 21
    		$-0.55$-0.55+0.00%Beat-553.5%
    Dec 20
    		$-0.16$0.00N/AMiss-84.5%
    Sep 20
    		$-0.18$0.00N/AMiss-86.1%
    Jun 20
    		$-0.14$0.00N/AMiss-60.3%
    Mar 20
    		$-0.08$0.00N/AMiss-15.8%
    Dec 19
    		$-0.09$0.00N/AMiss-13.2%
    Sep 19
    		$-0.10$0.00N/AMiss-8.5%
    Jun 19
    		$-0.09$0.00N/AMiss+1.4%
    Mar 19
    		$-0.07$0.00N/AMiss+10.6%
    Dec 18
    		$-0.08$0.00N/AMiss+13.7%
    Sep 18
    		$-0.09$0.00N/AMiss-333.5%
    Jun 18
    		$-0.09$0.00N/AMiss-340.8%
    Mar 18
    		$-0.08$0.00N/AMiss-59.3%
    Dec 17
    		$-0.09$0.00N/AMiss-75.8%
    Sep 17
    		$0.04$0.00N/ABeat+215.0%
    Jun 17
    		$0.04$0.00N/ABeat-
    Mar 17
    		$-0.05$0.00N/AMiss-
    Dec 16
    		$-0.05$0.00N/AMiss-
    Sep 16
    		$-0.03$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-13.29EV/EBITDA-5.78x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-10476.00%
    ROE-90.40%ROIC-204.04%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio7.42xQuick Ratio7.42x
    Trading Statistics
    Beta1.41Avg Volume1.79M
    52-Week High$17.5852-Week Low$4.19

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.59
    SMA 20$13.20
    SMA 50$11.42
    SMA 200$7.49
    EMA 10$13.45
    EMA 20$13.06
    EMA 50$11.53
    EMA 200$8.27

    MACD

    Line: 0.65Signal: 0.81Hist: -0.16

    ADX

    ADX: 42.9+DI: 28.5-DI: 12.1

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down24.0
    PSAR$17.58

    Bollinger Bands

    Upper Band$15.68
    Lower Band$10.73
    %B Position3750%(Upper)
    Band Width0.54

    RSI (14-Day)

    Neutral
    56.8

    Momentum Oscillators

    Stoch %K17.3
    Stoch %D26.1
    Williams %R-88.3
    ROC (10d)-2.2%
    Momentum-0.30
    CCI (20d)10.1
    MFI (14d)15.3

    Volatility Measures

    ATR (14d)$0.87(6.5%)
    StdDev (20d)1.24
    Hist Vol115.3%(High)

    Volume Flow

    VWAP$13.43
    OBV14.2M
    AD Line-8.4M
    CMF (20d)-0.385

    Volume Metrics

    Avg Vol (20d)1.9M
    Vol Ratio0.3x(Low)
    VWMA (20d)$14.39

    Pivot Points

    R3$13.96
    R2$13.82
    R1$13.64
    Pivot Point$13.50
    S1$13.31
    S2$13.17
    S3$12.99

    Advanced Oscillators

    TSI18.71
    Ultimate Osc41.1
    KST250.18

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$421,292$34,000$159,000$307,198$183,706$24.33M$1.14M$598,000$15.70M$2.10M$2.80M
    Cost of Revenue$108,195$116,803$12,000$64,000$116,570$69,860$1.61M$2.77M$2.64M$2.80M$1.35M$1.61M
    Gross Profit$-108,195$304,488$22,000$95,000$190,627$113,846$22.72M$-1,632,000$-2,040,000$12.90M$753,000$1.19M
    Operating Expenses$13.00M$15.33M$12.48M$26.34M$33.05M$36.87M$25.80M$20.91M$16.28M$18.48M$14.05M$13.89M
    R&D$8.31M$8.34M$8.75M$20.54M$24.20M$26.93M$20.40M$15.30M$10.99M$11.85M$9.94M$8.93M
    SG&A$4.69M$7.03M$3.73M$5.79M$7.04M$9.94M$5.40M$5.60M$5.29M$6.63M$4.12M$4.96M
    Operating Income$-13,110,705$-15,020,782$-12,461,000$-26,244,000$-32,863,337$-36,753,007$-3,078,390$-22,537,000$-18,323,000$-5,581,000$-13,299,000$-12,699,000
    Interest Income$0$0$0$0$0$0$0$981,000$1.06M$804,000$388,000$2.05M
    Interest Expense$0$0$0$0$4.64M$11.54M$11.54M$8.60M$183,000$13,000$928,000$8,000
    Income Before Tax$-12,289,219$-14,931,931$-11,770,000$-20,957,000$-37,500,108$-36,909,546$23.74M$-30,158,000$-17,441,000$-2,068,000$-14,966,000$-10,661,000
    Income Tax Expense$1,001$0$-1,000$1,000$13,714$9.56M$9.56M$-3,146,000$-1,879,000$244,000$-554,000$-2,411,000
    Net Income$-12,290,221$-14,931,931$-11,770,000$-20,958,000$-37,513,822$-36,909,546$14.17M$-27,012,000$-15,562,000$-2,312,000$-14,412,000$-8,250,000
    EBITDA$-13,002,510$-14,826,109$-11,657,000$-20,801,000$-30,844,607$-36,731,015$7.19M$-21,441,000$-17,139,000$-2,934,000$-14,908,000$-10,528,000
    EBIT$-13,110,705$-14,931,931$-11,770,000$-20,957,000$-31,047,577$-36,909,546$7.07M$-21,556,000$-17,258,000$-3,086,000$-15,029,000$-10,653,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SLN

    News

    Silence Therapeutics Plc (SLN) Stock Price | Live Quotes & Charts | NASDAQ

    This page provides live quotes and charts for Silence Therapeutics Plc (SLN) stock. It shows the current stock price, recent price changes, and historical data. The article also mentions the absence of analyst ratings and earnings information for the company, while promoting trading bootcamps and algorithmic trade alerts.

    StocksToTrade•8/26/26•
    Neutral

    Silence Therapeutics progresses rare blood cancer siRNA with positive trial results

    Silence Therapeutics has announced positive Phase II trial results for divesiran, an siRNA drug designed to treat polycythemia vera (PV), a rare blood cancer. The SANRECO trial met its primary endpoint, showing an 88% response rate in patients treated with divesiran compared to 19% in placebo groups, significantly reducing the need for frequent phlebotomies. The drug works by silencing the TMPRSS6 gene, controlling red blood cell production, and the company plans to advance to Phase III clinical trials with quarterly dosing.

    BioXconomy•8/21/26•
    Bullish

    Silence Therapeutics completes private fund raise at USD 201.3m for divesiran trial

    Silence Therapeutics has successfully completed an upsized public offering, raising approximately $201.3 million to fund the Phase III development of its lead siRNA asset, divesiran. This comes after positive Phase II data for divesiran in polycythemia vera patients. The company plans to initiate the Phase III trial for divesiran in the first half of 2027.

    AllSci•8/17/26•
    Bullish

    Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs

    Silence Therapeutics plc announced the closing of its upsized public offering, which included the full exercise of the underwriters' option to purchase additional American Depositary Shares (ADSs). The offering, consisting of 14,907,407 ADSs at $13.50 per ADS, generated gross proceeds of approximately $201.3 million. The company is a clinical-stage biotechnology firm focused on developing novel short interfering RNA (siRNA) therapies.

    www.marketscreener.com•8/17/26•
    Bullish

    Silence Therapeutics closes $201.3M public offering By Investing.com

    Silence Therapeutics plc (NASDAQ:SLN) has successfully closed an underwritten public offering, raising approximately $201.3 million. The offering included 14,907,407 American Depositary Shares at $13.50 per ADS, with underwriters fully exercising their option for additional shares. The gross proceeds will support the clinical-stage biotechnology company in its development of short interfering RNA therapies.

    Investing.com South Africa•8/15/26•
    Somewhat-Bullish

    Frequently Asked Questions About SLN

    Does SLN pay dividends?
    Silence Therapeutics PLC (SLN) does not currently pay a regular dividend.
    What is SLN's market cap?
    Silence Therapeutics PLC (SLN) has a market capitalization of $834.11M with a current stock price of $13.42.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In